Fresenius Medical Care (NYSE:FMS) Sees Unusually-High Trading Volume

Fresenius Medical Care AG (NYSE:FMS) shares saw unusually-strong trading volume on Friday . Approximately 725,833 shares changed hands during mid-day trading, an increase of 75% from the previous session’s volume of 415,394 shares.The stock last traded at $18.90 and had previously closed at $19.54.

Analysts Set New Price Targets

A number of analysts have recently weighed in on FMS shares. Truist Financial raised their price objective on Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research report on Wednesday, May 15th. StockNews.com assumed coverage on Fresenius Medical Care in a research report on Monday, June 17th. They set a “strong-buy” rating for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Trading Down 0.7 %

The company has a market cap of $11.38 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.04 and a beta of 0.93. The stock has a 50-day simple moving average of $20.81 and a 200 day simple moving average of $20.23. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 0.46.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.10. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. As a group, equities research analysts predict that Fresenius Medical Care AG will post 1.5 EPS for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Monday, June 3rd. Stockholders of record on Monday, May 20th were issued a $0.437 dividend. The ex-dividend date was Friday, May 17th. This represents a dividend yield of 2.35%. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 49.44%.

Hedge Funds Weigh In On Fresenius Medical Care

Institutional investors and hedge funds have recently modified their holdings of the stock. Envestnet Asset Management Inc. increased its stake in shares of Fresenius Medical Care by 362.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock valued at $5,580,000 after purchasing an additional 202,991 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of Fresenius Medical Care by 21.7% in the 3rd quarter. Clearbridge Investments LLC now owns 11,106 shares of the company’s stock valued at $239,000 after purchasing an additional 1,981 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Fresenius Medical Care in the 3rd quarter valued at about $332,000. O Shaughnessy Asset Management LLC increased its stake in Fresenius Medical Care by 259.5% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 92,635 shares of the company’s stock worth $1,995,000 after buying an additional 66,864 shares in the last quarter. Finally, Mckinley Capital Management LLC purchased a new stake in Fresenius Medical Care during the 3rd quarter worth approximately $297,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.